868555-43-5

Basic information

• Product Name: methyl 4′-((phenylamino)methyl)[1,1′-biphenyl]-2-carboxylate
• Synonyms: methyl 4′-((phenylamino)methyl)[1,1′-biphenyl]-2-carboxylate
• CAS NO: 868555-43-5
• Molecular Weight: 317.387
• Mol File: 868555-43-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 4′-((phenylamino)methyl)[1,1′-biphenyl]-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4′-((phenylamino)methyl)[1,1′-biphenyl]-2-carboxylate(868555-43-5)
• EPA Substance Registry System: methyl 4′-((phenylamino)methyl)[1,1′-biphenyl]-2-carboxylate(868555-43-5)

Safety Data

• Hazardous Substances Data: 868555-43-5(Hazardous Substances Data)

Upstream product

• 87199-17-5 4-formylphenylboronic acid, 
• 610-94-6 2-bromobenzoic acid methyl ester 
• 88-65-3 2-bromobenzoic-acid 
• 62-53-3 aniline 
• 144291-47-4 4-(2-Methoxycarbonyl-phenyl)-Benzaldehyde 

Relevant articles and documents

First Structure-Activity Relationship Study of Potent BLT2 Agonists as Potential Wound-Healing Promoters

The first potent leukotriene B4 (LTB4) receptor type 2 (BLT2) agonists, endogenous 12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT), and synthetic CAY10583 (CAY) have been recently described to accelerate wound healing by enhanced keratinocyte migration and indirect stimulation of fibroblast activity in diabetic rats. CAY represents a very valuable starting point for the development of novel wound-healing promoters. In this work, the first structure-activity relationship study for CAY scaffold-based BLT2 agonists is presented. The newly prepared derivatives showed promising in vitro wound-healing activity.

NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND

[PROBLEM] The compound that selectively binds to BLT2 and the preventive and/or therapeutic drug for BLT2-mediated disease such as skin disease are needed. [MEANS FOR SOLVING THE PROBLEMS] The present invention provides the compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof. Since the compound with BLT2 binding activity, particularly the compound represented by the formula (I) , salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.